Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Evaporative, Aqueous Deficient), By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Evaporative, Aqueous Deficient), By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030


Dry Eye Syndrome Treatment Market Growth & Trends

The global dry eye syndrome treatment market size is expected to reach USD 10.13 billion by 2030, registering a CAGR of 7.97% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.

The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.

ver-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.

Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.

Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.

Dry Eye Syndrome Treatment Market Report Highlights
  • By type, evaporative dry eye syndrome held the largest share in 2023 owing to the increasing prevalence of the condition and heightened screen time
  • Based on dosage form, eye drops held the largest revenue share in 2023 owing to easy availability as well as increased preference for eye drop administration of the product
  • By drug, Restasis held the largest market share in 2023 owing to its high adoption as a prescription drug for dry eye treatment
  • Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience
  • North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Treatment outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Market Variables, Trends, and Scope
3.1. Market Lineage
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. Dry Eye Syndrome Treatment Market - Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing geriatric population
3.2.1.2. Increasing Prevalence of Dry Eye Syndrome
3.2.1.3. Robust product pipeline
3.2.1.4. Growing disease awareness and increasing use of contact lenses
3.2.2. Market Restraint Analysis
3.2.2.1. Competition from generic products
3.2.2.2. High cost of treatments and lack of awareness among the general population in low- and middle-income countries
3.3. Business Environmental Tools Analysis: Dry Eye Syndrome Treatment Market
3.3.1. Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pipeline Analysis
3.5. Pricing Analysis
Chapter 4. Dry Eye Syndrome Treatment Market: Type Estimates & Trend Analysis
4.1. Dry Eye Syndrome Treatment Market: Type Dashboard
4.2. Dry Eye Syndrome Treatment Market: Type Movement Analysis
4.3. Dry Eye Syndrome Treatment Market Estimates and Forecasts, By Type, 2018 - 2030 (USD Million)
4.4. Evaporative Dry Eye Syndrome
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Aqueous Deficient Dry Eye Syndrome
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Dry Eye Syndrome Treatment Market: Drug Estimates & Trend Analysis
5.1. Dry Eye Syndrome Treatment Market: Drug Dashboard
5.2. Dry Eye Syndrome Treatment Market: Drug Movement Analysis
5.3. Dry Eye Syndrome Treatment Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)
5.4. Restasis
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Xiidra
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Cequa
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Eysuvis
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Tyrvaya
5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Dry Eye Syndrome Treatment Market: Product Estimates & Trend Analysis
6.1. Dry Eye Syndrome Treatment Market: Product Dashboard
6.2. Dry Eye Syndrome Treatment Market: Product Movement Analysis
6.3. Dry Eye Syndrome Treatment Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)
6.4. Cyclosporine
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Topical Corticosteroids
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Artificial Tears
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Punctal Plugs
6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Removable Punctal Plugs
6.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. Dissolvable Punctal Plugs
6.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Oral Omega Supplements
6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.9. Others
6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Dry Eye Syndrome Treatment Market: Dosage Form Estimates & Trend Analysis
7.1. Dry Eye Syndrome Treatment Market: Dosage Form Dashboard
7.2. Dry Eye Syndrome Treatment Market: Dosage Form Movement Analysis
7.3. Dry Eye Syndrome Treatment Market Estimates and Forecasts, By Dosage Form, 2018 - 2030 (USD Million)
7.4. Gels
7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Eye Solutions
7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Capsules & Tablets
7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Eye Drops
7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Ointments
7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Dry Eye Syndrome Treatment Market: Sales Channel Estimates & Trend Analysis
8.1. Dry Eye Syndrome Treatment Market: Sales Channel Dashboard
8.2. Dry Eye Syndrome Treatment Market: Sales Channel Movement Analysis
8.3. Dry Eye Syndrome Treatment Market Estimates and Forecasts, By Sales Channel, 2018 - 2030 (USD Million)
8.4. Prescription
8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.5. OTC
8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Dry Eye Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis
9.1. Dry Eye Syndrome Treatment Market: Distribution Channel Dashboard
9.2. Dry Eye Syndrome Treatment Market: Distribution Channel Movement Analysis
9.3. Dry Eye Syndrome Treatment Market Estimates and Forecasts, By Distribution Channel, 2018 - 2030 (USD Million)
9.4. Hospital Pharmacies
9.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
9.5. Online Pharmacies
9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
9.6. Retail Pharmacies
9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Dry Eye Syndrome Treatment Market: Regional Estimates & Trend Analysis
10.1. Dry Eye Syndrome Treatment Market: Regional Movement Analysis, 2022 & 2030
10.2. North America
10.2.1. North America Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.2.2. U.S.
10.2.2.1. Key Country Dynamics
10.2.2.2. Competitive Scenario
10.2.2.3. Prevalence Insights
10.2.2.4. Regulatory Framework
10.2.2.5. Reimbursement Structure
10.2.2.6. U.S. Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.2.3. Canada
10.2.3.1. Key Country Dynamics
10.2.3.2. Competitive Scenario
10.2.3.3. Prevalence Insights
10.2.3.4. Regulatory Framework
10.2.3.5. Reimbursement Structure
10.2.3.6. Canada Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3. Europe
10.3.1. Europe Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.2. UK
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Prevalence Insights
10.3.2.4. Regulatory Framework
10.3.2.5. Reimbursement Structure
10.3.2.6. UK Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.3. Germany
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Prevalence Insights
10.3.3.4. Regulatory Framework
10.3.3.5. Reimbursement Structure
10.3.3.6. Germany Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.4. France
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Prevalence Insights
10.3.4.4. Regulatory Framework
10.3.4.5. Reimbursement Structure
10.3.4.6. France Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.5. Italy
10.3.5.1. Key Country Dynamics
10.3.5.2. Competitive Scenario
10.3.5.3. Prevalence Insights
10.3.5.4. Regulatory Framework
10.3.5.5. Reimbursement Structure
10.3.5.6. Italy Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.6. Spain
10.3.6.1. Key Country Dynamics
10.3.6.2. Competitive Scenario
10.3.6.3. Prevalence Insights
10.3.6.4. Regulatory Framework
10.3.6.5. Reimbursement Structure
10.3.6.6. Spain Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.7. Denmark
10.3.7.1. Key Country Dynamics
10.3.7.2. Competitive Scenario
10.3.7.3. Prevalence Insights
10.3.7.4. Regulatory Framework
10.3.7.5. Reimbursement Structure
10.3.7.6. Denmark Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.8. Sweden
10.3.8.1. Key Country Dynamics
10.3.8.2. Competitive Scenario
10.3.8.3. Prevalence Insights
10.3.8.4. Regulatory Framework
10.3.8.5. Reimbursement Structure
10.3.8.6. Sweden Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.3.9. Norway
10.3.9.1. Key Country Dynamics
10.3.9.2. Competitive Scenario
10.3.9.3. Prevalence Insights
10.3.9.4. Regulatory Framework
10.3.9.5. Reimbursement Structure
10.3.9.6. Norway Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4. Asia Pacific
10.4.1. Asia Pacific Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4.2. Japan
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Prevalence Insights
10.4.2.4. Regulatory Framework
10.4.2.5. Reimbursement Structure
10.4.2.6. Japan Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4.3. China
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Prevalence Insights
10.4.3.4. Regulatory Framework
10.4.3.5. Reimbursement Structure
10.4.3.6. China Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4.4. India
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Prevalence Insights
10.4.4.4. Regulatory Framework
10.4.4.5. Reimbursement Structure
10.4.4.6. India Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4.5. Australia
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Prevalence Insights
10.4.5.4. Regulatory Framework
10.4.5.5. Reimbursement Structure
10.4.5.6. Australia Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4.6. Thailand
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Prevalence Insights
10.4.6.4. Regulatory Framework
10.4.6.5. Reimbursement Structure
10.4.6.6. Thailand Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.4.7. South Korea
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Prevalence Insights
10.4.7.4. Regulatory Framework
10.4.7.5. Reimbursement Structure
10.4.7.6. South Korea Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.5. Latin America
10.5.1. Latin America Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.5.2. Brazil
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Prevalence Insights
10.5.2.4. Regulatory Framework
10.5.2.5. Reimbursement Structure
10.5.2.6. Brazil Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.5.3. Mexico
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Prevalence Insights
10.5.3.4. Regulatory Framework
10.5.3.5. Reimbursement Structure
10.5.3.6. Mexico Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.5.4. Argentina
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Prevalence Insights
10.5.4.4. Regulatory Framework
10.5.4.5. Reimbursement Structure
10.5.4.6. Argentina Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.6. Middle East & Africa
10.6.1. Middle East & Africa Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.6.2. South Africa
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Prevalence Insights
10.6.2.4. Regulatory Framework
10.6.2.5. Reimbursement Structure
10.6.2.6. South Africa Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.6.3. Saudi Arabia
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Prevalence Insights
10.6.3.4. Regulatory Framework
10.6.3.5. Reimbursement Structure
10.6.3.6. Saudi Arabia Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.6.4. UAE
10.6.4.1. Key Country Dynamics
10.6.4.2. Competitive Scenario
10.6.4.3. Prevalence Insights
10.6.4.4. Regulatory Framework
10.6.4.5. Reimbursement Structure
10.6.4.6. UAE Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
10.6.5. Kuwait
10.6.5.1. Key Country Dynamics
10.6.5.2. Competitive Scenario
10.6.5.3. Prevalence Insights
10.6.5.4. Regulatory Framework
10.6.5.5. Reimbursement Structure
10.6.5.6. Kuwait Dry Eye Syndrome Treatment Market Estimates And Forecasts, 2018–2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Company Categorization
11.2. Company Market Share Analysis, 2022
11.3. Strategy Mapping
11.4. Company Profiles/Listing
11.4.1. NOVARTIS AG.
11.4.1.1. Overview
11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.1.3. Product Benchmarking
11.4.1.4. Strategic Initiatives
11.4.2. ABBVIE, INC.
11.4.2.1. Overview
11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.2.3. Product Benchmarking
11.4.2.4. Strategic Initiatives
11.4.3. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.4.3.1. Overview
11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.3.3. Product Benchmarking
11.4.3.4. Strategic Initiatives
11.4.4. SANTEN PHARMACEUTICAL CO., LTD.
11.4.4.1. Overview
11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.4.3. Product Benchmarking
11.4.4.4. Strategic Initiatives
11.4.5. AFT PHARMACEUTICALS
11.4.5.1. Overview
11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.5.3. Product Benchmarking
11.4.5.4. Strategic Initiatives
11.4.6. JOHNSON & JOHNSON SERVICES, INC.
11.4.6.1. Overview
11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.6.3. Product Benchmarking
11.4.6.4. Strategic Initiatives
11.4.7. OTSUKA PHARMACEUTICAL CO., LTD.
11.4.7.1. Overview
11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.7.3. Product Benchmarking
11.4.7.4. Strategic Initiatives
11.4.8. OASIS MEDICAL.
11.4.8.1. Overview
11.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.8.3. Product Benchmarking
11.4.8.4. Strategic Initiatives
11.4.9. OYSTER POINT PHARMA, INC.
11.4.9.1. Overview
11.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.9.3. Product Benchmarking
11.4.9.4. Strategic Initiatives
11.4.10. BAUSCH & LOMB
11.4.10.1. Overview
11.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.10.3. Product Benchmarking
11.4.10.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings